Ampio Pharmaceuticals Inc

ASE:AMPE   9:35:37 AM EDT
0.00 (0.00%)

Ampio Receives Feedback From FDA On Ampio's Proposed Modifications To Special Protocol Assessment For Ampion Treatment Of Severe Osteoarthritis Of Knee

Published: 12/29/2020 14:28 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Receives Feedback From the FDA on Ampio's Proposed Modifications to the Special Protocol Assessment for Ampion Treatment of Severe Osteoarthritis of the Knee.
Ampio Pharmaceuticals Inc - FDA Provided Practical Guidance for Ap-013 Study to Navigate Pandemic, and to Complete Study Without Re-running Trial.